---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-110336"
form_type: "8-K"
ticker: "ADGM"
cik: "0002006986"
company_name: "Adagio Medical Holdings, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:48:21.728849+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adagio Medical Q3 net loss $10.1M vs $4.6M; completes 209-patient VT trial, closes $50M placement

## Summary
- Net loss of $10.1M in Q3 2025, vs $4.6M in Q3 2024; cash $4.7M as of Sep 30, 2025.
- Completed enrollment of 209-patient FULCRUM-VT pivotal trial for vCLAS System VT ablation; demonstrated 97% acute effectiveness.
- Closed private placement on Oct 20, 2025 with gross proceeds up to $50M; upfront ~$19M to fund PMA submission.
- Appointed Deborah Kaster as Chief Financial Officer, adding to her role as Chief Business Officer.
- R&D expenses $2.8M; SG&A expenses $2.9M, down from $7.8M in prior year quarter.

## SEC filing metadata
- accession: 0001104659-25-110336
- form_type: 8-K
- ticker: ADGM
- cik: 0002006986
- company_name: Adagio Medical Holdings, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2006986/000110465925110336/0001104659-25-110336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2006986/000110465925110336/adgm-20251112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-110336
- JSON: https://secwatch.observer/filing/0001104659-25-110336.json
- Plain text: https://secwatch.observer/filing/0001104659-25-110336.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.